Inside the changing tides of life science research
Astellas Pharma chief medical officer Bernhardt Zeiher talks about the evolution of R&D in life sciences
Research and devolvement (R&D) scientists in life sciences are constantly on the lookout for innovations that will improve the likelihood of a successful end result. Over the past few decades, advancements in computing and technology have dramatically transformed the capabilities and capacity of life science R&D, a shift that has been fundamental in the emergence of concepts such as personalised medicine.
Patient-centricity is now a central pillar of innovation for many leading figures in life science. As such, scientists are beginning to adopt new processes in the lab, which reflect the changing needs of patients and health care professionals.
With 25 years of experience working in the pharmaceutical industry, Astellas chief medical officer, Bernhardt Zeiher, has been in a prime position to witness the transformation of R&D. As the industry lays the groundwork for a new era of health care, Zeiher explains how a global pandemic became a catalyst for change, putting patients at the heart of life science research.